VivoSim Labs, Inc.
VIVSNASDAQHealthcare● Active
$1.19
+$0.00(+0.00%)
Market Cap$3103472
P/E Ratio—
52W High$5.3
52W Low$1.16
VivoSim Labs, Inc. (VIVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VIVS · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 11, 2026EPS Actual
-$1.03
Est. -$2.40 · +57.1%
Revenue
$0.00B
Est. $0.00B · -48.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
VIVS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 29, 2026 | -$2.04 | — | — | — | $0.00B | — |
| ▲ Q1 FY2026 | Feb 11, 2026 | -$2.40 | -$1.03 | +57.1% | $0.00B | $0.00B | -48.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$2.28 | -$0.98 | +57.0% | $0.00B | $0.00B | -44.0% |
| — Q3 FY2025 | Aug 12, 2025 | — | -$1.14 | — | $0.00B | — | — |
| ▼ Q2 FY2025 | May 30, 2025 | -$2.28 | -$3.48 | -52.6% | $0.00B | — | — |
| ▲ Q1 FY2025 | Feb 19, 2025 | -$2.52 | -$0.19 | +92.5% | $0.00B | $0.00B | -45.5% |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.26 | -$0.14 | +46.1% | $0.00B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
-$2.04
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 11, 2026Beat
EPS Actual
-$1.03
EPS Est.
-$2.40
EPS Surpr.
+57.1%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.98
EPS Est.
-$2.28
EPS Surpr.
+57.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025
EPS Actual
-$1.14
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 30, 2025Miss
EPS Actual
-$3.48
EPS Est.
-$2.28
EPS Surpr.
-52.6%
Revenue
$0.00B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$2.52
EPS Surpr.
+92.5%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.26
EPS Surpr.
+46.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $-2.04 | $-2.04 | $-2.04 | 1 |
| Q4 FY2025 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q3 FY2025 | $-2.28 | $-2.28 | $-2.28 | 1 |
| Q2 FY2025 | $-2.28 | $-2.28 | $-2.28 | 1 |
| Q1 FY2025 | $-2.28 | $-2.28 | $-2.28 | 1 |
| Q4 FY2024 | $-2.52 | $-2.52 | $-2.52 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Feb 11, 2026 | +57.1% | $1.92 | $1.92 | +0.00% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +57.0% | $2.28 | $2.19 | -3.95% |
| — Q3 FY2025 | Aug 12, 2025 | — | $1.78 | $1.75 | -1.69% |
| ▼ Q2 FY2025 | May 30, 2025 | -52.6% | $1.86 | $1.80 | -3.23% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +92.5% | No price data | $1.72 | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | +46.1% | No price data | $1.72 | — |
| — Q2 FY2024 | Jun 30, 2024 | — | No price data | $1.72 | — |
| — Q1 FY2024 | Mar 31, 2024 | — | No price data | $1.72 | — |
Q1 FY2026+0.00%
Report Date
Feb 11, 2026
EPS Beat/Miss
+57.1%
Price Before
$1.92
Price After
$1.92
Q4 FY2025-3.95%
Report Date
Nov 6, 2025
EPS Beat/Miss
+57.0%
Price Before
$2.28
Price After
$2.19
Q3 FY2025-1.69%
Report Date
Aug 12, 2025
EPS Beat/Miss
—
Price Before
$1.78
Price After
$1.75
Q2 FY2025-3.23%
Report Date
May 30, 2025
EPS Beat/Miss
-52.6%
Price Before
$1.86
Price After
$1.80
Q1 FY2025—
Report Date
Feb 19, 2025
EPS Beat/Miss
+92.5%
Price Before
—
Price After
$1.72
Q4 FY2024—
Report Date
Nov 8, 2024
EPS Beat/Miss
+46.1%
Price Before
—
Price After
$1.72
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$1.72
Q1 FY2024—
Report Date
Mar 31, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$1.72
Avg Beat Reaction-1.98%
Avg Miss Reaction-3.23%
Beat Rate4 / 8 quarters
Largest Move-3.95% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VIVS ends December
VivoSim Labs, Inc. (VIVS) most recently reported earnings on February 11, 2026 for Q1 FY2026, posting EPS of $-1.03 — beating the analyst consensus of $-2.40 by +57.1%. VIVS has beaten EPS estimates for 2 consecutive quarters. The next VIVS earnings date is expected around September 1, 2026.
Each quarter, investors track VIVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VIVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VIVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VIVS earnings · 5 questionsVivoSim Labs, Inc.'s next earnings report is expected around September 1, 2026. VIVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VIVS historically reports after market close (AMC).
VIVS earnings datewhen is VIVS earningsVIVS next earnings datewhen does VIVS report earningsVIVS earnings calendar
▸ Source: FMP · VivoSim Labs, Inc. SEC filings · US GAAP · VivoSim Labs, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026